Cidara Therapeutics Net Profit Margin 2014-2022 | CDTX
Cidara Therapeutics net profit margin from 2014 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Cidara Therapeutics Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2022-09-30 |
$0.06B |
$-0.03B |
-55.74% |
| 2022-06-30 |
$0.03B |
$-0.06B |
-237.04% |
| 2022-03-31 |
$0.05B |
$-0.04B |
-77.78% |
| 2021-12-31 |
$0.05B |
$-0.04B |
-85.71% |
| 2021-09-30 |
$0.05B |
$-0.05B |
-106.52% |
| 2021-06-30 |
$0.04B |
$-0.05B |
-119.51% |
| 2021-03-31 |
$0.01B |
$-0.08B |
-690.91% |
| 2020-12-31 |
$0.01B |
$-0.08B |
-625.00% |
| 2020-09-30 |
$0.01B |
$-0.07B |
-670.00% |
| 2020-06-30 |
$0.03B |
$-0.05B |
-170.37% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.127B |
$0.050B |
|
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|
